US 12,226,403 B2
Tebipenem pivoxil immediate and modified release oral dosage forms
Akash Jain, Cambridge, MA (US); Enxian Lu, Shanghai (CN); Shaoqiong Lyu, Shanghai (CN); Shoufeng Li, North Brunswick, NJ (US); Timothy Keutzer, Cambridge, MA (US); Luke Utley, Cambridge, MA (US); Grazyna Fraczkiewicz, Lancaster, CA (US); and Joyce MacWan, Lancaster, CA (US)
Assigned to SPERO THERAPEUTICS, INC., Cambridge, MA (US)
Appl. No. 16/470,058
Filed by SPERO THERAPEUTICS, INC., Cambridge, MA (US)
PCT Filed Dec. 15, 2017, PCT No. PCT/US2017/066729
§ 371(c)(1), (2) Date Jun. 14, 2019,
PCT Pub. No. WO2018/112372, PCT Pub. Date Jun. 21, 2018.
Claims priority of provisional application 62/434,643, filed on Dec. 15, 2016.
Claims priority of provisional application 62/438,071, filed on Dec. 22, 2016.
Prior Publication US 2020/0016126 A1, Jan. 16, 2020
Int. Cl. A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/427 (2006.01)
CPC A61K 31/427 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2846 (2013.01)] 16 Claims
 
1. A tebipenem pivoxil HBr tablet core comprising at least 60% (w/w) tebipenem pivoxil, wherein tebipenem is the only therapeutic active agent.